NASDAQ:NRIX - Nurix Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $49.33
  • Forecasted Upside: 71.00 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$28.85
▲ +0.02 (0.07%)

This chart shows the closing price for NRIX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Nurix Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NRIX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NRIX

Analyst Price Target is $49.33
▲ +71.00% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Nurix Therapeutics in the last 3 months. The average price target is $49.33, with a high forecast of $60.00 and a low forecast of $40.00. The average price target represents a 71.00% upside from the last price of $28.85.

This chart shows the closing price for NRIX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 investment analysts is to buy stock in Nurix Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/20/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/18/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/14/2021SVB LeerinkInitiated CoverageOutperform$50.00Medium
7/15/2021Needham & Company LLCInitiated CoverageBuy$48.00Medium
4/30/2021Royal Bank of CanadaInitiated CoverageOutperform$42.00High
4/14/2021Berenberg BankInitiated CoverageBuyHigh
2/17/2021Needham & Company LLCReiterated RatingBuy$44.00Low
2/17/2021Piper SandlerBoost Price TargetOverweight$40.00 ➝ $60.00Low
1/29/2021JPMorgan Chase & Co.Boost Price TargetOverweight$34.00 ➝ $56.00Medium
1/8/2021Needham & Company LLCBoost Price TargetBuy$35.00 ➝ $44.00Low
11/18/2020Robert W. BairdInitiated CoverageOutperform$40.00Medium
8/18/2020JPMorgan Chase & Co.Initiated CoverageOverweight$35.00Low
8/18/2020Stifel NicolausInitiated CoverageBuy$34.00Low
8/18/2020Needham & Company LLCInitiated CoverageBuy$35.00Low
8/18/2020Piper SandlerInitiated CoverageOverweight$40.00Low
(Data available from 10/18/2016 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/21/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/20/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/20/2021
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/19/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/18/2021
  • 1 very positive mentions
  • 10 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
10/18/2021

Current Sentiment

  • 1 very positive mentions
  • 10 positive mentions
  • 5 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Nurix Therapeutics logo
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; DeTIL-0255 for tumor infiltrating lymphocytes therapy; KINASE-CTM3 to treat T cell malignancies and autoimmune diseases; and LIGASE-INH2 for immuno-oncology. In addition, the company develops programs, such as COVID-CTM1, COVID-CTM2, and COVID-CTM3 that are designed for protein degradation to SARs CoV2 targets. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $28.85
Low: $28.27
High: $29.10

50 Day Range

MA: $32.01
Low: $27.56
High: $36.69

52 Week Range

Now: $28.85
Low: $21.53
High: $52.38

Volume

1,409 shs

Average Volume

419,193 shs

Market Capitalization

$1.28 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.47

Frequently Asked Questions

What sell-side analysts currently cover shares of Nurix Therapeutics?

The following equities research analysts have issued stock ratings on Nurix Therapeutics in the last year: Berenberg Bank, JPMorgan Chase & Co., Needham & Company LLC, Piper Sandler, Robert W. Baird, Royal Bank of Canada, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for NRIX.

What is the current price target for Nurix Therapeutics?

6 Wall Street analysts have set twelve-month price targets for Nurix Therapeutics in the last year. Their average twelve-month price target is $49.33, suggesting a possible upside of 71.1%. Piper Sandler has the highest price target set, predicting NRIX will reach $60.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $40.00 for Nurix Therapeutics in the next year.
View the latest price targets for NRIX.

What is the current consensus analyst rating for Nurix Therapeutics?

Nurix Therapeutics currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NRIX will outperform the market and that investors should add to their positions of Nurix Therapeutics.
View the latest ratings for NRIX.

What other companies compete with Nurix Therapeutics?

How do I contact Nurix Therapeutics' investor relations team?

The company's listed phone number is 415-660-5320 and its investor relations email address is [email protected] The official website for Nurix Therapeutics is www.nurixtx.com.